U.S. Drug Enforcement Administration and the People’s Republic of China Hold Bilateral Drug Intelligence Working Group Meeting in Colorado Springs, Colorado
Washington - The U.S. Drug Enforcement Administration in coordination with federal partners and the People’s Republic of China convened the Bilateral Drug Intelligence Working Group (BDIWG) in Colorado Springs February 10 to 12, 2026. This working group brought together law enforcement, prosecutors, customs, border security, public security, financial supervision, and technical experts to advance practical cooperation against the global threat of illicit synthetic drugs, including fentanyl, and the criminal networks that profit from them.
The shared, urgent, and life‑saving priority to stem fentanyl and other synthetic opioids has been emphasized by both President Trump and President Xi.
The working group reviewed recent progress and agreed on concrete next steps to disrupt chemical supply chains, prevent diversion, and target illicit finance tied to transnational criminal organizations. This included a look at drug trafficking trends in both countries, the impact of precursor chemicals on the drug supply, pill presses and related equipment, and the role of online advertising.
DEA was joined by representatives from the Department of Justice, Department of Homeland Security, Department of the Treasury, and U.S. Customs and Border Protection along with counterparts from China’s Ministry of Public Security (MPS), China Customs, Supreme People’s Procuratorate, People’s Bank of China, and staff from key provincial police bureaus.
Recognizing the terrible human toll of synthetic drugs, in particular fentanyl, the United States and China are committed to working together, in line with the guidance from both countries’ leaders, to save lives, protect communities, and uphold the rule of law.